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Bladder urothelial cell carcinoma (UCC) incidence is about three times
higher in men compared with women. There are several indications for the
involvement of hormonal factors in the aetiology of UCC. Here, we pro-
vide evidence of androgen signalling in UCC progression. Microarray and
qPCR analysis revealed that the androgen receptor (AR) mRNA level is
upregulated in a subset of UCC cases. In an AR-positive UCC-derived cell
line model, UM-UC-3-AR, androgen treatment increased clonogenic
capacity inducing the formation of big stem cell-like holoclones, while AR
knockdown or treatment with the AR antagonist enzalutamide abrogated
this clonogenic advantage. Additionally, blockage of AR signalling reduced
the cell migration potential of androgen-stimulated UM-UC-3-AR cells.
These phenotypic changes were accompanied by a rewiring of the tran-
scriptome with almost 300 genes being differentially regulated by andro-
gens, some of which correlated with AR expression in UCC patients in two
independent data sets. Our results demonstrate that AR signals in UCC
favouring the development of an aggressive phenotype and highlights its
potential as a therapeutic target for bladder cancer.
1. Introduction
Bladder urothelial cell carcinoma (UCC) is the 12th
most commonly diagnosed malignancy worldwide and
the 14th leading cause of cancer death among men
and women [1]. UCC had an estimated 424 082 new
cases in 2018 and in the same year, despite improve-
ments in surgical techniques and perioperative care
over the last decades, there were 148 270 predicted
deaths due to UCC [1]. Clinically, UCC can be divided
into nonmuscle invasive bladder cancer (NMIBC) and
muscle-invasive bladder cancer (MIBC), accounting
Abbreviations
ADT, androgen deprivation therapy; AR, androgen receptor; CIS, in situ carcinoma; Cp, crossing point; CSS, charcoal-stripped serum; CYP,
cytochrome P450; FDR, false discovery rate; GSEA, gene set enrichment analysis; ICC, immunocytochemistry; IHC, immunohistochemistry;
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for ~ 75% and 25% of the cases, respectively. NMIBC
is characterized by a high recurrence rate of 30–80%
in 5 years and a risk of progression to MIBC disease
of 3–15% [2]. MIBC often progresses to metastatic dis-
ease, explaining the low 5-year survival rate of about
50% after diagnosis of MIBC [3]. Identification of
molecular factors involved in the development and
progression of UCC is an unmet need that can help to
improve diagnosis, treatment and monitoring of UCC.
Although UCC is not considered a hormone-related
type of cancer, there are indications of the involvement
of hormonal factors in the aetiology of bladder cancer.
The incidence of UCC in men is approximately three-
fold higher than in women [4–6]. For many years, this
ratio was explained by the excessive exposure of men
to carcinogens from cigarette smoke and industrial
chemicals. However, even after correcting for these
factors, the sex-related difference persists [4]. Remark-
ably, this phenomenon can be reproduced in UCC ani-
mal models where carcinogen-induced bladder
tumours developed three times more often in male
than in female mice [7].
Steroids are key mediators of sex-specific differences.
Androgens, the male sex steroids, exert their function
through binding to the androgen receptor (AR). The
AR is a transcription factor that plays a key role in
the development and maintenance of male sexual
organs. The androgen and AR signalling pathway is
well known for its contribution to the progression of
prostate cancer (PCa), and androgen deprivation ther-
apy (ADT) is a first-line treatment for advanced PCa
[8]. Surgical castration of mice prior to carcinogen
treatment also significantly reduced bladder tumour
formation, and knockout of the AR gene completely
prevented bladder carcinogenesis [9]. Interestingly,
recent retrospective studies involving PCa patients that
received ADT have shown that the risk of recurrence
of concomitant bladder cancer was significantly
reduced [10,11]. Although the precise mechanisms by
which the AR contributes to the development and pro-
gression of UCC remain poorly understood, these
results highlight the importance and potential clinical
relevance of elucidating the function of AR signalling
in UCC.
Here, we profiled the expression of AR in various
nonmalignant bladder and UCC specimens to correlate
AR levels with gender and tumour stage. Next, we
investigated the role of AR in several cancer-related
pathways using a new AR-positive bladder cancer cell
line model, UM-UC-3-AR. Finally, we have defined
the transcriptome signature accompanying phenotypi-
cal changes driven by androgen/AR signalling and
used expression data from UCC patients to pin point
those genes of potential clinical relevance. Our results
provide new insights into the role of the AR in UCC
proposing novel therapeutic routes for the treatment
of this disease.
2. Materials and methods
2.1. Patient specimens
The experiments were undertaken with the understand-
ing and written consent of each subject. The use of
patient materials and the study methodologies were
approved by the local ethics committee of the Rad-
boud University Medical Center (CMO Arnhem-
Nijmegen) and conformed to the standards set by the
Declaration of Helsinki. Upon transurethral resection
of tumour tissue or cystectomy, specimens were snap-
frozen in liquid nitrogen. For microarray analysis, nor-
mal bladder (NB, n = 12), NMIBC in situ carcinoma
(CIS, n = 6), Ta (n = 37) and T1 (n = 11), and MIBC
T2 (n = 27), T3 (n = 14) and T4 (n = 13) specimens
were used. For qPCR validation, independent samples
were used, including NB (n = 5), CIS (n = 1), Ta
(n = 14), T1 (n = 4), T2 (n = 7), T3 (n = 6) and T4
(n = 4). Normal bladder urothelium was obtained by
macrodissection of benign urothelium from NMIBC
bladder cancer specimens. Specimens were processed
by step sectioning and selected for purity of benign
(99–100%) or cancer cells (at least 70%). Patient and
tumour characteristics can be found in Tables S1,S2.
2.2. RNA isolation
Total RNA was isolated using TRIzol reagent, accord-
ing to the manufacturer’s instructions (Thermo Fisher
Scientific, Landsmeer, the Netherlands). Concentration
and purity of the RNA were determined on a Nano-
Drop 1000 Spectrophotometer.
2.3. Microarray analysis
Microarray gene expression analysis on these tissue
samples was performed and described previously [12].
Normalized log2 values were used to determine AR
gene expression in those specimens.
2.4. Real-time semi-quantitative RT-qPCR
For RT-qPCR analysis, 2 µg of DNase I-treated total
RNA was used to generate cDNA, using random hex-
amer primers (Roche, Almere, the Netherlands) and
SuperScript II Reverse Transcriptase (Invitrogen,
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Landsmeer, the Netherlands). Real-time PCR analysis
was performed using LightCycler 480 SYBR Green I
Master Mix and a LightCycler 480 Machine (Roche).
Crossing-point (Cp) values were determined using the
LightCycler 480 SW 1.5 software (Roche). RNA not
subjected to reverse transcriptase was used as a nega-
tive control. The average Cp values from two different
experimental runs were used for the analysis. Expres-
sion levels of HP1BP3 or HPRT1 were used for nor-
malization. Relative gene expression levels were
calculated according to Pfaffl et al. [13]. Primers for
RT-qPCR can be found in Table S3.
2.5. Immunostaining
For immunohistochemistry (IHC), 4-µm-thick UCC
tissue sections containing > 50% epithelial cells were
cut. For immunocytochemistry (ICC), 5637, T24, 253J,
UM-UC-3 and UM-UC-3-AR cells (8000/well) were
seeded in Lab-Tek II 8-Well Chamber Slides (Thermo
Fisher). For AR nuclear translocation experiments,
cells were seeded in androgen-deprived medium. After
24 h, cells were treated for 24 h with 10 nM R1881
(Organon, Oss, the Netherlands) or EtOH (0.1%) as
vehicle control. Cells were fixed with 4%
paraformaldehyde and left to dry overnight. Slides
with fixed tissue (IHC) or cells (ICC) were exposed to
boiling 10 mM sodium citrate (pH 6.0) for 10 min. The
rabbit polyclonal AR antibody N20 (Santa Cruz, SC-
816, Heidelberg, Germany) was diluted 1 : 5000 in
PBS/1% BSA and incubated for 1 h at room tempera-
ture, followed by exposure to Poly-HRP goat anti-Ms/
Rb/Rt IgG (DPVO110HRP, Immunologic) solution
diluted 1 : 1 in PBS/1% BSA for 30 min. Slides were
incubated with Bright-DAB (Immunologic) for
10 min, counterstained with haematoxylin and
mounted in Permount Mounting Medium (Thermo
Fisher Scientific).
2.6. Cell culture
The UM-UC-3 cell line was purchased from the
ATCC (CRL-1749, Molsheim Cedex, France). The
fully AR-positive UM-UC-3-AR line was obtained
from the UM-UC-3 parental line by clonal selection.
UM-UC-3 and UM-UC-3-AR cells were cultured in
Dulbecco’s modified Eagle medium with 1 gL1 D-glu-
cose, 4 mM L-glutamine and 1 mM pyruvate, supple-
mented with 10% FCS (Sigma) and 1x nonessential
amino acids (Gibco, Landsmeer, the Netherlands). The
5637 (HTB-9), T24 (HTB-4), 253J [14] and LNCaP
(CRL-1740) cell lines were cultured in Roswell Park
Memorial Institute 1640 Medium, supplemented with
2 mM L-glutamine and 10% FCS. All cell cultures were
maintained in a humidified atmosphere at 37 °C and
5% CO2. Cells were frequently tested for Mycoplasma
infection, using a Mycoplasma-specific PCR. All cell
lines were authenticated using the PowerPlex 21 Sys-
tem (Promega, Leiden, the Netherlands) by Eurofins
Genomics (Germany) and propagated for no more
than 6 months or 30 passages after resuscitation from
the authenticated stocks.
2.7. Western blot analysis
A total of 1.2 9 106 of UM-UC-3, UM-UC-3-AR,
LNCaP and 5637 cells were seeded per well in 6-well
plates. Twenty four hours later, cells were lysed using
Laemmli lysis buffer (1 mM CaCl2, 2% SDS, 60 mM
Tris/glycine pH 6.8) supplemented with 300 mM b-mer-
captoethanol. Lysates were homogenized by sheering
them through a 0.5 9 25-mm syringe needle. The pro-
tein concentration was measured after staining with
Coomassie Brilliant Blue (Merck, Amsterdam, the
Netherlands) using BSA as a standard. A total of
50 µg of protein was used for SDS/PAGE using 7.5%
polyacrylamide gels. Proteins were electrotransferred
onto PVDF membranes (Hybond 0.45 µm; Amersham
Biosciences, Buckinghamshire, UK). Membranes were
blocked for 1 h in PBS-T/5% nonfat dry milk and
incubated overnight with the primary antibody. The
rabbit polyclonal AR antibody N20 (Santa Cruz, SC-
816) and the mouse monoclonal antibody anti-b-actin
(Sigma-Aldrich; clone AC-15) were diluted 1 : 50 000
and 1 : 5000 in PBS-T/5% nonfat dry milk, respec-
tively. The PO-conjugated donkey anti-rabbit antibody
(Amersham Biosciences, N4934) or sheep anti-mouse
antibody (Amersham Biosciences, NXA931) diluted
1 :50 000 in PBS-T was used as secondary antibodies.
Protein bands were detected using the ECL Detection
Kit and Hyperfilm (Amersham Biosciences).
2.8. Karyotyping
UM-UC-3 and UM-UC-3-AR were seeded in T25 cul-
ture flasks until reaching 40% confluency. Cells were
arrested in metaphase by exposing them to
0.2 µgmL1 of KaryoMAX (Life Technologies, Blei-
jswijk, the Netherlands) for 30 min. From each cell
line, five metaphases were fully analysed by GTG
banding at ~ 450 band level to exclude gross chromo-
somal aberrations. Count and analysis of chromosome
marks were manually executed using reference marks
described for UM-UC-3 by the ATCC: m1 = der(1)t
(1;?) (p32;?), m2 = ?t(1p5p), m3 = i(3q), m4 = t(7q14q)
and m5 = ?t(2p3p).
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2.9. Glycine repeat and gene copy number
Genomic DNA from UM-UC-3 and UM-UC-3-AR
was isolated using the QIAaMP DNA Mini Kit (Qia-
gen, Venlo, the Netherlands) following the manufac-
turer’s instructions. For amplification of the AR gene
glycine repeat region, Phusion High-Fidelity Poly-
merase and the Phusion High-Fidelity buffer special-
ized for GC-rich regions (Thermo Fisher) and primers
listed in Table S4 were used. The purified DNA was
subjected to Sanger DNA sequencing. Gene copy
number was determined by qPCR analysis using geno-
mic DNA as a template and primers against AR,
SPIN4, PCA3 and GAPDH intronic regions. PCA3
and GAPDH were used for normalization. Normalized
AR and SPIN4 copy numbers were adjusted to those
from healthy female genomic DNA. Copy number of
both genes from a benign prostate hyperplasia speci-
men was used as a control.
2.10. KLK3 luciferase reporter assay
A total of 10 000 cells/well were seeded in FCS-contain-
ing medium in 96-well plates in triplicate. Transfection
mix containing 90 ng of the pCMV-PSA85-Luc Repor-
ter Construct (kindly provided by J. Trapman; Erasmus
MC, Rotterdam), 10 ng of the pRL-TK Renilla (Pro-
mega) control vector, and X-tremeGENETM 9 Transfec-
tion Reagent (Roche) was added per well. One day
after transfection, 0.1 or 0.5 nM of R1881 (Organon)
was added to the medium in combination with 1 or
5 µM enzalutamide (Selleck Chemicals, Houston, TX,
USA), respectively. DMSO and EtOH (< 1%) were
used as vehicle controls. The luciferase activities were
measured 16 h later using the Dual-Luciferase Reporter
Assay System (Promega). Luciferase signals were mea-
sured on a VVICTOR3 Multilabel Reader (Perkin
Elmer, Groningen, the Netherlands).
2.11. Small interfering RNA Transfection
Silencer Select small interfering RNAs (siRNAs) direc-
ted against the AR and a negative control No. 1
siRNA were used (Ambion, Bleijswijk, the Nether-
lands; Table S5). Cells were transfected with siRNAs
at a 20 nM final concentration using Lipofectamine
RNAiMAX Transfection Reagent according to the
manufacturer’s protocol (Thermo Fisher Scientific).
2.12. Colony formation assay
UM-UC-3 and UM-UC-3-AR cells were seeded in 6-
well plates at a density of 250 cells/well and cultured
in medium containing 0.1 nM R1881 (Organon) in
combination with 1 µM enzalutamide (Selleck Chemi-
cals). DMSO and EtOH (0.2%) were used as vehicle
controls. For siRNA experiments, 200 000 cells were
seeded and transfected as described above. One day
post-transfection, cells were harvested and reseeded in
6-well plates in the presence of 0.1 nM R1881. Medium
was refreshed after 1 week. After 14 days, colonies
were washed with PBS, fixed with 3% paraformalde-
hyde, and stained with 0.01% crystal violet (Merck)
for 60 min. The number and size of colonies were
analysed using the FIJI software [15]. Morphological
analysis of colonies was done using light microscopy.
2.13. Cell proliferation assay
A total of 10 000 cells/well were seeded in 96-well
plates in triplicate, in charcoal-stripped serum (CSS)-
containing medium to wash away traces of androgens
previously reported to be present in FCS [16]. One day
after seeding, 0.1 nM of synthetic androgen R1881
(Organon) was added to the medium in combination
with 1 µM enzalutamide (Selleck Chemicals). DMSO
and EtOH (0.2%) were used as vehicle controls. For
siRNA experiments, 10 000 cells/well were seeded and
transfected as described above. One day after transfec-
tion, cells were treated with R1881 and enzalutamide
at concentrations described before. Cell viability was
measured at regular time intervals using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(1 mgmL1) assays. Doubling time was calculated
using the Doubling Time tool at www.doubling-time.c
om.
2.14. Cell migration assay
A total of 70 000 UM-UC-3 or UM-UC-3-AR cells
were seeded per well in a 24-well plate CSS-containing
medium. One day after seeding, cells were treated with
0.1 nM R1881 (Organon) in combination with 1 µM
enzalutamide (Selleck Chemicals). DMSO and EtOH
(0.2%) were used as vehicle controls. For siRNA-me-
diated AR knockdown, siRNA transfection was per-
formed 24 h after seeding. Treatment with 0.1 nM
R1881 started 24 h after transfection. When cells
reached 100% confluency (72 h after hormonal manip-
ulation), a wound was made by mechanically scratch-
ing the cell monolayer with a 1-mL pipette tip.
Medium was replaced, and cells were allowed to
migrate into the cell-free area. Wound size was mea-
sured at regular time intervals, and cell migration was
calculated using the difference in wound size between
each time point.
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2.15. RNA sequencing sample preparation
For RNA sequencing analysis, samples were purified
using an RNeasy RNA Extraction Kit (Qiagen) with
DNase I treatment. Total RNA (1 µg per sample) was
used for library preparation using the RNA Hyper-
Prep Kit with RiboErase (KAPA Biosystems, Almere,
the Netherlands). A fragmentation step was carried
out for 6.5 min, and NEXTFLEX DNA barcodes
(Sanbio, Uden, the Netherlands) were used for adapter
ligation. Libraries were amplified using 10 amplifica-
tion cycles. Library concentration was measured using
the dsDNA Fluorescence Quantification Assays
(DeNovix, Wilmington, Delaware, the Netherlands),
and library size was determined using the BioAnalyzer
High Sensitivity DNA Kit (Agilent, Amstelveen, the
Netherlands). Sequencing was performed using an Illu-
mina NextSeq 500, and 50-bp paired-end reads were
generated.
2.16. RNA sequencing analysis
Paired-end reads were aligned to the human GRCh38
genome (Release 95—January 2019) using the STAR
RNA-seq aligner version 2.4.0 [17], with –sjdbOver-
hang set to 100. Mapped reads were counted with
HTSeq count [18] with the following settings: -r pos –s
reverse –t exon. Differential gene expression was deter-
mined with DESeq2 [19], and genes with a false dis-
covery rate (FDR) < 0.05 were considered to be
differentially expressed. Visualization was performed
using the Complex Heatmap package [20].
2.17. Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was done using
the GSEA software supplied by the Broad Institute
[21]. The gene lists from R1881 (Organon)/enzalu-
tamide (Selleck Chemicals) or siControl/siAR were
ranked based on the fold change after shrinkage using
DESeq2 [19]. The Hallmarks of Cancer gene set data-
base was used with permutations set to 1000 to deter-
mine the FDR. Normalized enrichment scores (NESs)
were obtained after analysis.
2.18. TCGA data
Expression data (FPKM values) of AR and of andro-
gen-responsive genes identified in UM-UC-3-AR are
available from the public The Cancer Genome Atlas
(TCGA) database, containing 408 MIBC cases
(Tables S6,S7). The clinical and expression data were
downloaded from cBioPortal [22].
2.19. Statistical analyses
The data of bar and dot plots are presented as
means  SEM from at least three independent experi-
ments. Two-tailed paired and unpaired t-tests were per-
formed using GRAPHPAD PRISM (GraphPad Software,
Inc., San Diego, CA, USA). A P-value of < 0.05 was
considered statistically significant, and P < 0.05 is repre-
sented by one star (*), P < 0.01 is represented by two
stars (**), P < 0.001 is represented by three stars (***)
and P < 0.0001 is represented by four stars (****).
For correlations of TCGA data, FPKM values were
log2-transformed (values equal to 0 were added +1
before transformation). Spearman’s correlation of
log2-transformed expression values (TCGA or microar-
ray) was calculated using the R package psych [23]. A
correlation was considered statistically significant when
having an FDR < 0.05 and valid when the correlation
coefficient was higher than 0.3 or lower than 0.3
[24]. The built-in R function prcomp from the package
stats [25] was used to perform the principal component
analysis (PCA) and ggplot2 from the package tydiverse
[26] was used for visualization of results.
3. Results
3.1. AR is upregulated in a subset of UCC cases
To profile the expression of AR mRNA in urothelial
bladder tissue, we performed a microarray analysis on
NMIBC (CIS, and tumours of Ta and T1 stage),
MIBC (tumours of T2, T3 and T4 stages) and nonma-
lignant bladder urothelial specimens. A subset of UCC
tissue samples (27/108) expressed AR mRNA at levels
above those from nonmalignant tissue (Fig. 1A). AR
mRNA expression was significantly higher in NMIBC
compared with MIBC tissues (Fig. 1B), and a trend
towards lower AR expression and tumour stage was
observed. The number of male UCC cases was about
three times higher than female cases (Fig. S1A), but
no significant difference in AR expression was
observed between the two groups (Fig. S1B). A techni-
cal validation by RT-qPCR, including additional UCC
cases, confirmed the association between AR expres-
sion and low stage UCC observed in the microarray
data (Table S8). More than 55% of the UCC cases
(21/36) have AR mRNA levels above nonmalignant
tissue, and 70% of those were NMIBC cases (Fig. 1C,
D). Also in the validation cohort, no significant differ-
ence in AR mRNA levels was observed between male
and female cases (Fig. S1C,D). To assess AR protein
expression and localization, we performed IHC
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analysis on tumour sections from the MIBC (T3) spec-
imen with the highest AR mRNA expression from our
microarray cohort, using the AR N and C terminus-
specific antibodies, N20 and Ep670Y, respectively. A
heterogeneous population of AR-positive and AR-
negative tumour cells was observed. In the AR-positive
cells, the AR was located in the nucleus. Androgen
stimulation promotes AR nuclear translocation, a pre-
requisite for AR-mediated transcriptional activity, and






Fig. 1. AR expression in urothelial bladder (cancer) tissue samples. (A) Microarray analysis showing AR gene expression profiles in
nonmalignant bladder (NB, n = 12), NMIBC in situ (CIS, n = 6), Ta (n = 37) and T1 (n = 11), and MIBC T2 (n = 27), T3 (n = 14) and T4
(n = 13). Microarray values (log2) shown as the mean  SEM of each group are depicted. Unpaired t-test; *, P < 0.05; **, P < 0.01.
Horizontal dotted line marks the median = 5 and separates high-AR from low-AR tumour samples. A subset of UCC tissue samples (27/108)
express AR mRNA at levels above upper limit from the 95% confidence interval (CI) of AR expression in nonmalignant tissue. (B) Median
AR expression values (log2) from microarray data in NMIBC (n = 54) and MIBC (n = 54). Unpaired t-test; **, P < 0.01. (C) AR mRNA
expression obtained by RT-qPCR and normalized to that of HP1BP3 in nonmalignant bladder (NB, n = 5) and in CIS (n = 1), Ta (n = 14), T1
(n = 4), T2 (n = 7), T3 (n = 6) and T4 (n = 4) tumour specimen. Horizontal dotted line marks the median = 0.26 and separates high- from
low-AR samples. A subset of UCC tissue samples (21/36) express AR mRNA at levels above upper limit from the 95% CI of AR expression
in nonmalignant tissue. Unpaired t-test; **, P < 0.01. (D) Median AR expression values in NMIBC (n = 19) and MIBC (n = 17). Unpaired t-
test; *, P < 0.05. (E) Immunohistochemical analysis of an UCC T3 tumour stained with the AR N20 antibody (N terminus-specific) and
Ep670Y antibody (C terminus-specific). Haematoxylin was used as nuclear counterstain. The dotted rectangular area is 409 magnified and
the upper images 20x.
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3.2. UM-UC-3-AR as a new AR-positive UCC-
derived cell line model
For functional experiments, we assessed AR expression
in the previously described AR-positive bladder carci-
noma-derived cell line models 253J, T24 and UM-UC-
3 [26,27]. All three cell lines expressed AR at low
levels, several orders of magnitude lower than the PCa
cell line LNCaP. Of the three UCC cell lines, UM-
UC-3 showed the highest AR expression (Fig. 2A). At
the protein level, all three cell lines showed very weak
AR protein expression levels, almost indistinguishable
from AR-negative 5637 cells (Fig. 2A). ICC analysis
revealed that 253J, T24 and UM-UC-3 cells are very
heterogeneous populations with roughly 3% of cells






Fig. 2. AR expression and signalling in UM-UC-3-AR. (A and C) Relative AR mRNA expression levels determined by RT-qPCR and
normalized to that of HP1BP3 in UCC-derived cell lines 253J, 5637, T24, UM-UC-3 and UM-UC-3-AR and in LNCaP PCa cells. Western blot
analysis of AR protein levels detected by AR N terminus antibody N20. Protein levels of b-actin (anti-b-actin) were used as a protein loading
control. (B) ICC analysis of AR in LNCaP, 253J, 5637, T24, UM-UC-3 and UM-UC-3-AR cells grown in FCS-containing medium. Cells were
stained with the N20 antibody, and haematoxylin was used as nuclear counterstain. Scale bar represents 100 µm. (D) Karyotyping analysis
of UM-UC-3 and UM-UC-3-AR cells arrested in metaphase. Genotype, number of chromosomes and chromosomal markers are depicted. (E)
AR and SPIN4 gene copy numbers determined by qPCR using genomic DNA from UM-UC-3 and UM-UC-3-AR cells, benign prostate
hyperplasia (BPH) and white blood cells from a healthy female. PCR values of the X-linked genes were normalized to PCR values of the
autosomal PCA3 and GAPDH genes, and then normalized to the ratio found in female cells. (F) Cellular localization of the AR protein in UM-
UC-3-AR cells grown in androgen-depleted medium and treated with 10 nM R1881 or vehicle control. Cells were stained with the N20
antibody (brown), and haematoxylin was used as nuclear counterstain. (G) KLK3 reporter activity in UM-UC-3, UM-UC-3-AR and LNCaP cells.
Cells were transfected with the PSA85-Luc firefly luciferase reporter vector and the pRL-TK Renilla luciferase control vector. Cells were
grown in FCS-containing medium and treated with R1881 in combination with enzalutamide or vehicle control. Bars represent the
mean  SEM of three independent experiments performed in triplicate. Unpaired t-test; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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subcloned using limited dilution, in order to obtain a
fully AR-positive cell line (UM-UC-3-AR). UM-UC-3-
AR expressed AR in more than 90% of the cells
(Fig. 2B), and this percentage remained constant for
over 40 passages (data not shown). At the mRNA
level, expression of AR was 40 times higher in UM-
UC-3-AR than in the parental line UM-UC-3
(Fig. 2C). These AR levels were comparable to those
in AR-positive UCC tissue and nonmalignant bladder
urothelium, respectively (Fig. S2A). AR mRNA
expression in UM-UC-3 and UM-UC-3-AR was con-
sistent with the difference observed at protein levels
(Fig. 2C). Using five chromosome markers described
for parental UM-UC-3, karyotyping analysis con-
firmed that the UM-UC-3-AR clone is derived from
parental UM-UC-3 (Fig. 2D). These data indicate that
UM-UC-3-AR is an UM-UC-3-derived AR-positive
UCC cell line model.
To determine whether the elevated AR mRNA levels
in UM-UC-3-AR were a consequence of AR gene
amplification, qPCR of genomic DNA of UM-UC-3
and UM-UC-3-AR was performed. Both cell lines car-
ried two copies of the AR gene, resulting from a dupli-
cation of the X chromosome (Fig. 2E). The AR gene
contains two repeat regions within the N-terminal
domain: a glutamine (CAG) and a glycine (GGC)
tract. More than 16 glycine (GGC) copies have been
demonstrated to form a hairpin structure that inhibits
translation [29]. Both UM-UC-3 and UM-UC-3-AR
carried 17 glycine repeats in exon 1 of the AR gene
(Fig. S2B). Although these results do not explain the
AR expression difference between the two cell lines,
they further underscore that UM-UC-3-AR is derived
from UM-UC-3.
Nuclear staining of AR in UM-UC-3-AR cells
(Fig. 2B) could be due to androgens present in the
FCS-containing medium that was used for these exper-
iments. The androgen levels present in FCS are suffi-
cient to promote AR activation in PCa cell lines [16].
To show that AR nuclear translocation in UM-UC-3-
AR is indeed a response to androgen stimulation, cells
were cultured in CSS-containing media and media
containing the synthetic androgen R1881. In andro-
gen-depleted medium (CSS), the AR protein was
found in the cytoplasm of UM-UC-3-AR cells,
whereas androgen stimulation promoted its transloca-
tion into the nucleus (Fig. 2F). A similar response was
observed in parental UM-UC-3 cells (Fig. S2C).
Sequencing analysis did not identify mutations in
the AR gene from UM-UC-3-AR (data not shown),
indicating that it should encode for a functional pro-
tein. As a transcription factor, the main role of AR is
to promote transcriptional activation of AR-targeted
genes. The KLK3 gene, encoding the prostate-specific
antigen (PSA), is a well-established AR-responsive
gene [30]. By using a KLK3 luciferase reporter con-
struct, we were able to monitor AR-mediated tran-
scription in UM-UC-3, UM-UC-3-AR and LNCaP
cells. In a dose-dependent manner, androgen stimula-
tion significantly increased AR-mediated transcrip-
tional activity observed in FCS-containing media in
UM-UC-3-AR and LNCaP, but not in UM-UC-3 cells
(Fig. 2G). Treatment with enzalutamide, a new-genera-
tion AR antagonist, at on-target doses [31,32], signifi-
cantly decreased transcriptional activity of AR in UM-
UC-3-AR and LNCaP, but not in parental UM-UC-3
cells (Fig. 2G). Altogether, these results indicate that
UM-UC-3-AR cells express a functional AR.
3.3. AR signalling induces colony formation in
UCC-derived cell line
Androgens stimulate cell proliferation in PCa cells
[33]. Therefore, we assessed whether androgens could
promote proliferation of the UCC-derived UM-UC-3-
AR cell line. Treatment with R1881 reduced doubling
time of LNCaP cells, whereas the addition of enzalu-
tamide reverted the effect. Neither treatment, however,
had an effect on UM-UC-3 or UM-UC-3-AR cell pro-
liferation (Fig. S3A). Likewise, siRNA-mediated
knockdown of AR resulted in a significant increase in
the doubling time of hormone-stimulated LNCaP cells,
but had no effect on UM-UC-3-AR cells (Fig. S3B)
despite an AR knockdown of about 80% and 50% at
Fig. 3. Androgen/AR-dependent UM-UC-3-AR colony formation. (A) Representative images of colony-forming assays of UM-UC-3 and UM-
UC-3-AR cells grown in androgen-depleted medium and treated with 0.1 nM R1881 with or without 1 µM enzalutamide, compared with
vehicle control conditions. (B) Relative clonogenic capacity of UM-UC-3 and UM-UC-3-AR cells that were treated with 0.1 nM R1881 in
combination with 1 µM enzalutamide or vehicle control. Bars represent the mean  SEM of three independent experiments performed in
triplicate. Paired t-test; *, P < 0.05; **, P < 0.01. (C) Illustration of holoclone and paraclone morphology. Representative light microscopy
images of UM-UC-3 and UM-UC-3-AR colonies after hormonal manipulation. (D) Light microscopic images of UM-UC-3-AR colonies that
were grown in R1881 medium following AR knockdown. Upper images, 209 magnification; dotted circles mark regions visualized at 40x
magnification (lower images). (E) Percentage of holoclone and paraclone colonies formed by UM-UC-3-AR cells following hormonal
manipulation (shown in C) or after siRNA-mediated AR knockdown (shown in D). Bars represent the mean  SEM of three independent
experiments performed in triplicate. Unpaired t-test; ***, P < 0.001.
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the RNA and protein levels, resp. (Fig. S3C,D).
Remarkably, androgen treatment increased the clono-
genic capacity of UM-UC-3-AR, but not of parental
UM-UC-3 cells, and addition of enzalutamide abro-
gated this clonogenic advantage (Fig. 3A,B). Based on
their morphology and growth potential, individual
clones can be classified into holoclones (holo = entire),
paraclones (para = beyond) or meroclones
(mero = partial) [34,35]. Morphological analysis of the
colonies showed that UM-UC-3 colonies had irregular
edges, and scattered and flattened cells. These so-called
paraclones were also observed with UM-UC-3-AR
colonies in androgen-depleted conditions (Fig. 3C). In
contrast, androgen stimulation of UM-UC-3-AR
induced the formation of tightly packed, round holo-
clones with better defined borders (Fig. 3C). To our
surprise, although AR knockdown did not achieve a
significant effect in the overall colony formation
(Fig. S3E,F), it did significantly increase the number
of UM-UC-3-AR paraclones despite hormone stimula-
tion (Fig. 3D,E). These data indicate that the morpho-
logic changes observed in UM-UC-3-AR were
dependent on both AR and androgens.
3.4. AR increases cell migration capacity of UM-
UC-3-AR
Among the three types of colonies, holoclones have the
greatest growth potential [34]. The ability of UM-UC-3-
AR cells to form big colonies with a holoclone-like mor-
phology in response to androgen stimulation proposes a
role of AR signalling in the acquisition of a more
aggressive phenotype. In addition to the high clonogenic
capacity of aggressive tumour cells, these cells often gain
cell migratory and invasive properties. Therefore, we
evaluated the effect of AR signalling on UM-UC-3-AR
cell migration using a scratch assay. Indeed, hormone
stimulation increased migration of UM-UC-3-AR cells
and this effect was reverted upon treatment with enzalu-
tamide (Fig. 4A,B) or upon siRNA-mediated knock-
down of AR expression (Fig. 4C,D). Cell migration of
parental UM-UC-3 cells was not affected by androgen
and AR modulation (Fig. S4).
3.5. Androgen/AR signalling in UM-UC-3-AR
Active AR signalling should impact transcriptional out-
put. To study the androgen/AR-driven gene expression
dynamics in the UM-UC-3-AR, we analysed transcrip-
tome data obtained by RNA sequencing of hormone-
stimulated cells and compared this to the gene expression
profile obtained after enzalutamide treatment or AR
knockdown. Clustering analysis revealed 285 differentially
expressed genes (FDR < 0.05) (Fig. 5A, Table S9). A
total of 163 genes displayed an androgen-responsive
pattern (cluster 1 and 3, Fig. 5A), with 69 of them
being dependent on both androgen and AR signalling
(cluster 1, Fig. 5A). Among these genes were FKBP5
and GREB1, known AR-targeted genes. Curiously, a
subset of genes were significantly downregulated upon
AR knockdown but not by enzalutamide treatment
(cluster 2, Fig. 5A), possibly indicating nongenomic
(i.e. non-nuclear) AR signalling, which has been previ-
ously described in PCa [35]. To disentangle gene
expression signatures from our transcriptome analysis,
GSEA was performed. Transcripts of genes involved
in hypoxia, glycolysis, bile acid metabolism, oestrogen
response and androgen response constituted the gene
expression signature associated with androgen and AR
signalling in our UCC cell line model (Fig. 5B). Col-
lectively, these results confirm an active androgen/AR
signalling in UM-UC-3-AR cells.
We next assessed the expression levels of all andro-
gen-responsive genes that were identified in UM-UC-3-
AR, in our UCC cohort. Expression values of AR and
265 out of 284 genes were present in our microarray
data set (Table S10). First, we separated our microarray
UCC cases into high-AR (n = 48; NMIBC = 30 and
MIBC = 18) and low-AR (n = 49; NMIBC = 18 and
MIBC = 31), using median AR expression as a cut-off.
We then compared the median expression levels of the
androgen-responsive genes between these two groups. A
total of 128/265 genes from our UCC cohort displayed
an expression pattern we defined as consistent with the
regulation observed in UM-UC-3-AR. In brief, from
the genes downregulated by enzalutamide treatment
and/or upon siRNA-mediated AR knockdown in UM-
UC-3-AR 75/175 showed similar expression dynamics
to AR in the high-AR and low-AR groups. From the
genes upregulated after enzalutamide treatment and/or
AR knockdown in our cell line model, the expression of
53/90 genes was higher in the low-AR group compared
with the high-AR group (Table S11). A Spearman cor-
relation test between AR and these 128 genes revealed
two gene clusters (Fig. S5A), one composed of genes
negatively correlating with AR (cluster 1) and one of
genes that positively correlated with AR (cluster 2).
From the genes, which expression significantly
(FDR < 0.05) correlated with AR levels, 15 genes had a
correlation coefficient > 0.3 or < 0.3 (Fig. 5C,
Table S12). In an independent cohort of 408 MIBC
cases, from the TCGA database, 123/254 genes were
consistent with the regulation observed in UM-UC-3-
AR (Table S13) and 86 of these were among those pre-
viously identified in our microarray cohort (Fig. 5D).
Four genes, namely PPP1R3C, CYP4F12, RERE and
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PLAU, had a correlation coefficient > 0.3 or < 0.3 in
both data sets (Table S14). As expected, PPP1R3C,
CYP4F12 and RERE were significantly upregulated in
the high-AR compared with the low-AR group from
both cohorts, while PLAU, was significantly downregu-
lated in the high- vs low-AR cases in both data sets
(Fig. S5B). These results propose a role for AR in the
regulation of these four genes in UCC.
3.6. Influence of subclass and gender in
androgen/AR regulation in UCC
An expression heat map of AR, PPP1R3C, CYP4F12,
RERE and PLAU revealed that the correlation of
expression of AR and PPP1R3C, CYP4F12, RERE
and PLAU was stronger in MIBC compared with
NMIBC tissue Fig. 6A). Indeed, clustering analysis
showed that separation of patients based on expression
of PPP1R3C, CYP4F12, RERE and PLAU clearly
separated the high- and low-AR groups in the TCGA
cohort (Fig. 6A). To further verify these findings, we
performed a PCA. The first two principal components
(PCs) in NMIBC described 58.35% of the variance in
the data and PC2, which explained 27.32% of the
data, was driven by AR expression (Fig. 6B). Interest-
ingly, analysis of the PC loadings showed that in PC2
PPP1R3C, CYP4F12, RERE and PLAU seemed to
drive separation of the patients in an opposite
A B
C D
Fig. 4. Effect of AR signalling in the migration capacity of UM-UC-3-AR. (A) Migration of UM-UC-3-AR cells as determined by scratch
assays. Cells were grown in androgen-depleted media and treated with 0.1 nM R1881 in combination with 1 µM enzalutamide (Enz) or
vehicle control. Light microscopic images taken at 0 and 24 h after scratching (409 magnification). (B) Relative cell migration of UM-UC-3-
AR cells as determined by scratch assays. Decrease in wound size at individual time points compared to t = 0 was measured and used to
calculate the migration capacity of cells. Unpaired t-test; *, P < 0.05; **, P < 0.01. (C) Migration of UM-UC-3-AR cells 96 h after siRNA-
mediated AR knockdown in medium containing 0.1 nM R1881. Light microscopic images taken at 0 and 24 h after scratching. (D) Relative
cell migration of UM-UC-3-AR cells following siRNA-mediated AR knockdown. Unpaired t-test; *, P < 0.05. Bars represent the mean  SEM
of three independent experiments performed in triplicate.
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direction than AR. On the contrary, PC1 from MIBC
cases, which explained 52.17% of the variance in the
data, separates patients mainly on the bases of AR
levels and shows that AR, PPP1R3C, CYP4F12 and
RERE drive this separation in an opposite direction
than PLAU. All five genes contributed to segregation
of the data with loadings greater than 0.3 or lower
than 0.3. Similar results were observed in the PCA
from the MIBC cases from TCGA (Fig. 6B). Lastly,
also in the TCGA group AR expression was not signif-
icantly different between genders (Fig. 6C). Despite
this, the expression of RERE was significantly lower in
women compared with men, in both our microarray
and the TCGA data sets (Fig. 6C). No other signifi-
cant association was found between AR, PLAU,
PPP1R3C, CYP4F12 or RERE, and other clinical fea-
tures available (data not shown).
4. Discussion
AR signalling is one of the main drivers of sex differ-
ences and is suggested to be involved in bladder car-
cinogenesis [9,37,38]. Here, we provide evidence that
the androgen/AR signalling axis is active and pro-
motes the development of an aggressive phenotype in
an UCC-derived cell line model. Like other UCC-
derived cell lines, the UM-UC-3 cell line contains a
low percentage of cells that are strongly AR-positive.
Using limited dilution, UM-UC-3 cells were subcloned
to obtain a fully AR-positive cell line (UM-UC-3-AR).
A B
C D
Fig. 5. Transcriptome dynamics in UM-UC-3-AR following androgen stimulation or AR knockdown. (A) Two row-matched heat maps (left)
and a detailed heat map of cluster 1 (right). Rows show Z-scores of mRNA abundance from significantly changing genes (FDR < 0.05). UM-
UC-3-AR cells were stimulated with 0.1 nM R1881 or DMSO vehicle control (V) in combination with 1 µM enzalutamide (E). Cluster 1 shows
genes that are differentially expressed in both comparisons; cluster 2 shows genes that are only significantly changing after knockdown of
AR; cluster 3 shows genes that are only significantly changing after androgen stimulation. (B) GSEA revealing pathways significantly
enriched in R1881/enzalutamide (Enz) and siControl/siAR conditions (FDR < 0.01). Androgen response is underlined (red) as a positive
control. NESs are shown. (C) Genes significantly correlating with AR mRNA expression (FDR < 0.05) with a correlation coefficient of > 0.3
or < 0.3 in our UCC microarray data set. Matrix shows correlation coefficients from each intersection. A description of the type of
regulation observed for each gene in UM-UC-3-AR is depicted. (D) Venn diagram displaying the number of genes that showed expression
dynamics similar to those observed in UM-UC-3-AR, in our microarray and in the TCGA data sets. Number in the intersection represents
those genes in common between both data sets, and lower circles describe the type of regulation observed in UM-UC-3-AR for this group
of genes.
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Based on the AR mRNA levels, UM-UC-3 and UM-
UC-3-AR represent the UCC cases with low- and
high-AR expression levels, respectively. Both lines
UM-UC-3 and UM-UC-3-AR contain the same num-
ber of glycine repeats within exon 1, the same number
of X chromosomes and the same AR gene copy num-
ber. Thus, additional levels of gene regulation should
underlie the different AR mRNA expression levels in
these two isogenic cell lines, which also could explain
the differences in AR levels found in bladder tumours.
Although AR levels in UM-UC-3-AR were signifi-
cantly lower than those in LNCaP, reflecting difference
between UCC and PCa patients, these levels were suf-
ficient to mediate phenotypic changes. Ligand-bound
AR regulated the clonogenic capacity of UM-UC-3-
AR cells. Androgen stimulation resulted in the forma-
tion of big-sized holoclones. Addition of AR inhibitor
enzalutamide significantly reduced colony formation,
and similarly to siRNA-mediated knockdown, it
resulted in the generation of small paraclones. PCa-
derived cells, seeded at low densities, have been shown
to form three different colony morphologies in vitro
that can be classified as holoclones, meroclones and
paraclones. These morphologies are suggested to repre-
sent stem cells, early progenitor cells and late progeni-
tor cells, respectively [34,35]. The formation of big
colonies from UM-UC-3-AR upon hormonal stimula-
tion reflects the self-renewal ability of holoclones.
A B
C
Fig. 6. Influence of subclass and gender in the androgen/AR signalling in UCC. (A) Row-matched heat maps of expression values of AR,
PPP1R3C, CYP4F12, RERE and PLAU from our microarray NMIBC (left) and MIBC (centre) cases and from MIBC (right) from TCGA data.
Columns show Z-scores of log2 expression values. Rows correspond to individual patients. (B) Principal component analysis (PCA) of
microarray NMIBC (left), MIBC (center) and MIBC from TCGA (right) cases separated based on expression of AR, PPP1R3C, CYP4F12,
RERE and PLAU. Loadings for each PCA are depicted below. (C) Median AR and RERE expression values (log2) from microarray UCC cases
in high-AR men (n = 34), high-AR women (n = 14), low-AR men (n = 35) and low-AR women (n = 14), and from TCGA data in high-AR men
(n = 157), high-AR women (n = 47), low-AR men (n = 144) and low-AR women (n = 60). Unpaired t-test; *, P < 0.05; **, P < 0.01; and ***,
P < 0.001.
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Likewise, the formation of colonies from single cells
reflects the capacity of cells to grow independent of
cell-to-cell interactions, also characteristic of cells with
increased cell migration capabilities [39]. Together, this
suggests that both AR-mediated effects in cell migra-
tion and colony formation in UM-UC-3-AR are
tightly linked.
With these phenotypic changes, several genes were
significantly upregulated upon hormone stimulation,
among which some previously described for their role
in promoting migration and colony formation of
diverse type of cancer models such as FKBP5, LDH-A,
GREB1, PDLIM1, TNK2, VASP, ARHGAP31 and
ZHX3 [40–47], and genes known to drive the develop-
ment of cancer cells with stem cell-like characteristics
such as TFCP2L1 and SH3RF3 [48,49]. These genes
were consistently downregulated upon treatment with
enzalutamide or after AR knockdown, which validates
them as androgen-responsive genes.
Androgen treatment of UM-UC-3-AR cells also
induced expression of NNMT and LDHA, genes previ-
ously reported to be upregulated in UCC patients
[50,51], and of BCL6 and H19, whose high expression
in UCC is associated with an adverse prognosis
[52,53]. Consistently, loss of or reduced expression of
SOCS6 and SEMA3F, genes downregulated upon
androgen treatment in our model, is associated with a
malignant phenotype in UCC [54,55]. These studies
are in agreement with the phenotype observed in our
UCC model, and it presents the AR signalling axis as
a novel regulatory mechanism for the expression of
these genes in UCC.
GSEA demonstrated that transcriptome dynamics
observed in UM-UC-3-AR indeed correspond to an
androgen response signature, which included genes
encoding for the AR co-regulators PIAS1 and CCND3
[56,57], and AR-interacting partners CDK6, NDRG1
and FKPB5 [58–60]. The hypoxia-inducible gene
LDH-A was also part of the hypoxia signature in our
enrichment analysis, the pathway with highest NES in
response to androgen stimulation. LDH-A relates to
stem cell function and is associated with poor postra-
diotherapy outcome in UCC [61]. The oestrogen
response pathway was also associated with an andro-
gen- and AR-dependent response in our UCC cell line
model. Cross-talk between steroid receptor pathways
has been described, and target genes often harbour
response elements for multiple steroid receptors [62].
Indeed, the AR target gene GREB1 was first reported
to be oestrogen-responsive [63] and later shown also to
be regulated by androgens through AR-mediated tran-
scription [64]. Other signatures shown in this study
have been linked to UCC development and
progression before. Perturbed bile acid biosynthesis
[65] and elevated glycolysis [66] have been reported in
UCC tumours. The activation of aerobic glycolysis
provides energy to cancer cells and supports their ana-
bolic growth. However, further research is needed to
understand the exact mechanisms by which AR regu-
lates the expression of genes associated with these
pathways.
Four genes CYP4F12, PPP1R3C, RERE and PLAU
defined as androgen-responsive in UM-UC-3-AR sig-
nificantly correlated with AR in two independent UCC
data sets. The CYP4F12 gene encodes a member of
the cytochrome P450 (or CYP) superfamily of
enzymes, which are involved in the synthesis of choles-
terol and steroids (e.g. androgens), and in drug meta-
bolism. The latter function being particularly
important in tissues regularly exposed to disposal
products (e.g. medicine metabolites, carcinogens) such
as the bladder. Indeed, deregulation of some CYP pro-
teins has been proposed as a risk factor for the devel-
opment of bladder cancer [67,68], but little is known
about the role of CYP4F12, in particular, in bladder
cancer progression. Interestingly, CYP4F12 mRNA
expression was shown to be downregulated upon treat-
ment with AR inhibitors enzalutamide or ARN-509 in
PCa-derived cells [69], in line with the results observed
in UM-UC-3-AR. Transcript levels of PPP1R3C, a
gene that encodes a protein involved in glycogen syn-
thesis and part of the ‘hypoxia’ and the ‘myogenesis’
signatures from our GSEA, were also shown before to
be androgen-responsive [70], as opposed to PLAU, a
gene that is known to be downregulated by androgens
in PCa models [71]. Both reports are consistent with
the observations in our UCC-derived cell line. Lastly,
upregulation of RERE mRNA as a consequence of
miR-22 inhibition resulted in increased migration and
cell proliferation in colon cancer [72]. Curiously,
downregulation of this tumour suppressor microRNA
has been associated with hypermethylation of miR-22
genomic AR-binding sites in PCa [73]. Although these
reports strengthen the link between AR and these four
genes, the direct or indirect role of AR protein in the
regulation of CYP4F12, PPP1R3C, RERE and PLAU
transcription and function in UCC is yet to be eluci-
dated.
Our transcriptome data also revealed a cluster of
androgen-responsive genes downregulated upon AR
knockdown that were not affected by enzalutamide
treatment. Enzalutamide promotes the accumulation
of AR in the cytosol [74], which could potentiate
nongenomic (i.e. non-nuclear) AR signalling. In the
cytoplasm, ligand-bound AR interacts with protein
kinases such as SRC and PI3K via its N terminus to
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initiate signal transduction pathways that modulate
cellular proliferation and migration in prostate cancer
cell lines. This process has been reported to be unre-
sponsive to AR antagonists such as enzalutamide [36].
The transcriptional response in cluster 2 from our
UCC cell line, however, is different than that described
for nongenomic AR signalling in PCa, and thus, future
studies are required to unravel the cytoplasmic func-
tions of AR in UCC.
A negative association between AR expression and
tumour stage has been reported before, both at the
mRNA and protein levels [75]. Indeed, transition into
muscle-invasive stages has been proposed to be ini-
tially regulated by AR and as the disease advances it
acquires an AR-independent profile [76]. Our patient
data showed that AR mRNA levels were significantly
upregulated in NMIBC compared with MIBC. The
lower frequency of AR-positive cases in MIBC also
suggests that AR-independent but androgen-dependent
mechanisms support high stage disease. Certainly, a
recent publication has shown that the SLC39A9 mem-
brane protein acts as an AR that, when activated by
androgens, increases migration and invasion of AR-
negative MIBC cells in vitro and in vivo [77]. Our tran-
scriptome data also revealed a cluster of genes being
regulated by androgens in an AR-independent manner.
Thus, ADT directed to lower systemic androgen levels
may be effective in most MIBC cases.
Several studies, including ours, reported that the
incidence of UCC is three to four times higher in men
than in women [5,6]. However, discrepancies exist in
the number of AR-positive UCC cases [75,78], which
could be explained by differences in patient popula-
tions and detection methods used in different studies.
All of our bladder specimens expressed AR mRNA
levels, both in the microarray analysis and in the RT-
qPCR validation. A subset of UCC tumours, both
NMIBC and MIBC, expressed AR mRNA levels
above those detected in nonmalignant bladder urothe-
lium specimens. Our in vitro data indicate that andro-
gen/AR signalling is involved in the acquisition of a
more aggressive phenotype of bladder tumour cells
and that it can be reverted with blockage of AR
signalling, advocating the potential benefits of AR-
targeted therapy for UCC. In low-grade NMIBC,
AR-targeted therapy may prevent the recurrence of
disease, and in high-grade NMIBC and MIBC, it may
prevent progression. Indeed, in PCa patients with con-
comitant NMIBC, progression of NMIBC to MIBC
was only reported in patients who did not receive
ADT as a treatment for their prostate tumour [11].
Furthermore, our correlation data suggest a relevance
for AR signalling at late stage of UCC. This means
ADT could be relevant to those MIBC described in
our study, which expressed high-AR mRNA levels.
Together, our data provide new understandings in the
role of androgens and AR signalling in UCC and sug-
gest that ADT is a realistic option for the treatment
of this disease.
5. Conclusions
Our study provides biological evidence of AR sig-
nalling in UCC with several pathways being differen-
tially regulated in response to androgen treatment.
Ligand-bound AR activates canonical and noncanoni-
cal AR target genes and potentiates migration and col-
ony formation. The contribution of AR to the
development of an aggressive phenotype in UCC high-
lights its potential clinical relevance as a novel thera-
peutic target.
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